OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
haixia完成签到,获得积分10
刚刚
刚刚
刚刚
Darline完成签到 ,获得积分10
刚刚
刚刚
按时毕业的小林完成签到,获得积分10
刚刚
1秒前
whhzzz发布了新的文献求助10
1秒前
1秒前
1秒前
clcl发布了新的文献求助10
2秒前
搞怪秋烟完成签到,获得积分10
2秒前
evak完成签到,获得积分10
2秒前
暮雨杰泽完成签到 ,获得积分10
3秒前
盒盒盒发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
lyt发布了新的文献求助10
4秒前
123完成签到,获得积分10
4秒前
徐磊完成签到,获得积分10
4秒前
manjusaka完成签到,获得积分10
4秒前
英勇的哲瀚完成签到,获得积分10
5秒前
癫狂梦醒完成签到,获得积分10
5秒前
沐雨应助跳跃毒娘采纳,获得10
5秒前
zhonglv7应助跳跃毒娘采纳,获得10
6秒前
asdfqwer应助不爱读书的采纳,获得10
6秒前
zhonglv7应助跳跃毒娘采纳,获得10
6秒前
6秒前
zhonglv7应助跳跃毒娘采纳,获得10
6秒前
沐雨应助跳跃毒娘采纳,获得10
6秒前
苟活着完成签到,获得积分10
6秒前
6秒前
张可爱发布了新的文献求助10
6秒前
任性铅笔完成签到,获得积分10
6秒前
王正正完成签到,获得积分10
6秒前
威武的帆布鞋完成签到,获得积分10
7秒前
7秒前
7秒前
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Burger's Medicinal Chemistry, Drug Discovery and Development, Volumes 1 - 8, 8 Volume Set, 8th Edition 1800
Cronologia da história de Macau 1600
Contemporary Debates in Epistemology (3rd Edition) 1000
International Arbitration Law and Practice 1000
文献PREDICTION EQUATIONS FOR SHIPS' TURNING CIRCLES或期刊Transactions of the North East Coast Institution of Engineers and Shipbuilders第95卷 1000
BRITTLE FRACTURE IN WELDED SHIPS 1000
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 纳米技术 计算机科学 化学工程 生物化学 物理 复合材料 内科学 催化作用 物理化学 光电子学 细胞生物学 基因 电极 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6159652
求助须知:如何正确求助?哪些是违规求助? 7987796
关于积分的说明 16601613
捐赠科研通 5268138
什么是DOI,文献DOI怎么找? 2810845
邀请新用户注册赠送积分活动 1790976
关于科研通互助平台的介绍 1658067